Cancer immunotherapy is generating huge excitement, but the future may lie elsewhere, in antibody–drug conjugates, proteolysis-targeting chimeras, and liquid biopsy for early detection.
Nature Medicine
Paul Webster
19 April 2022
Preview
By the numbers, it is easy to see why.
Since 2015, the US Food and Drug Administration (FDA) has approved more than 80 new anti-cancer drugs, or about a quarter of its total new drug approvals.
Oncology clinical trial starts reached historically high levels in 2020, up 60% from 2015, and focused mostly on rare cancer indications.
More than 700 companies are involved.
Across the globe, an estimated 19,500 cancer clinical trials are underway, propelled in good part by a huge expansion in China, and by an increase in global spending on anti-cancer drugs, which is projected to reach US$269 billion by 2025.
Original publication https://www.nature.com
Across the globe, an estimated 19,500 cancer clinical trials are underway, propelled in good part by a huge expansion in China, and by an increase in global spending on anti-cancer drugs, which is projected to reach US$269 billion by 2025.
